A Comprehensive Expression Analysis of Mucins in Appendiceal Carcinoma in a Multicenter Study: MUC3 is a Novel Prognostic Factor

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2015 Jan 1

PMID 25551773

Citations 14

Authors

Hiroaki Shibahara

Michiyo Higashi

Seiya Yokoyama

Karine Rousseau

Iwao Kitazono

Masahiko Osako

Hiroshi Shirahama

Yukie Tashiro

Yasuhiro Kurumiya

Michihiko Narita

Shingo Kuze

Hiroshi Hasagawa

Takehito Kato

Hitoshi Kubota

Hideaki Suzuki

Toshiyuki Arai

Yu Sakai

Norihiro Yuasa

Masahiko Fujino

Shinji Kondo

Yoshichika Okamoto

Tatsuyoshi Yamamoto

Takashi Hiromatsu

Eiji Sasaki

Kazuhisa Shirai

Satoru Kawai

Koutarou Hattori

Hideki Tsuji

Osamu Okochi

Masaki Sakamoto

Akinobu Kondo

Naomi Konishi

Surinder K Batra

Suguru Yonezawa

Affiliations

Soon will be listed here.

Abstract

Background: Mucins are implicated in survival in various cancers, but there have been no report addressed on survival in appendiceal carcinoma, an uncommon disease with different clinical and pathological features from those of other colon cancers. We aimed to investigate the clinical implications of expression of mucins in appendiceal carcinoma.

Methods: Expression profiles of MUC1, MUC2, MUC3, MUC4, MUC5AC, MUC6, MUC16 and MUC17 in cancer tissue were examined by immunohistochemistry in 108 cases of surgically resected appendiceal carcinoma.

Results: The following relationships of mucins with clinicopathologic factors were identified: MUC1 with positive lymphatic invasion (p = 0.036); MUC2 with histological type (mucinous carcinoma, p<0.001), superficial invasion depth (p = 0.007), negative venous invasion (p = 0.003), and curative resection (p = 0.019); MUC3 with non-curative resection (p = 0.017); MUC5AC with histological type (mucinous carcinoma, p = 0.002), negative lymphatic invasion (p = 0.021), and negative venous invasion (p = 0.022); and MUC16 with positive lymph node metastasis (p = 0.035), positive venous invasion (p<0.05), and non-curative resection (p = 0.035). A poor prognosis was related to positive lymph node metastasis (p = 0.04), positive lymphatic invasion (p = 0.02), positive venous invasion (p<0.001), non-curative resection (p<0.001), and positive expression of MUC3 (p = 0.004). In multivariate analysis, positive venous invasion (HR: 6.93, 95% CI: 1.93-24.96, p = 0.003), non-curative resection (HR: 10.19, 95% CI: 3.05-34.07, p<0.001) and positive MUC3 expression (HR: 3.37, 95% CI: 1.13-10.03, p = 0.03) were identified as significant independent prognostic factors in patients with appendiceal carcinoma.

Conclusions: Expression of MUC3 in appendiceal carcinoma is an independent factor for poor prognosis and a useful predictor of outcome in patients with appendiceal carcinoma after surgery.

Citing Articles

Defining a 'cells to society' research framework for appendiceal tumours.

Holowatyj A, Overman M, Votanopoulos K, Lowy A, Wagner P, Washington M Nat Rev Cancer. 2025; .

PMID: 39979656 DOI: 10.1038/s41568-024-00788-2.

Mutational Features and Tumor Microenvironment Alterations in High-Grade Appendiceal Cancers Treated With Iterative Hyperthermic Intraperitoneal Chemotherapy.

Su D, Dhiman A, Bansal V, Zha Y, Shergill A, Polite B JCO Precis Oncol. 2024; 8:e2400149.

PMID: 39259912 PMC: 11432692. DOI: 10.1200/PO.24.00149.

Expression patterns of HNF4α, TTF-1, and SMARCA4 in lung adenocarcinomas: impacts on clinicopathological and genetic features.

Kawai H, Miura T, Kawamatsu N, Nakagawa T, Shiba-Ishii A, Yoshimoto T Virchows Arch. 2024; 486(2):343-354.

PMID: 38710944 PMC: 11876232. DOI: 10.1007/s00428-024-03816-6.

Extent of Resection and Long-Term Outcomes for Appendiceal Adenocarcinoma: a SEER Database Analysis of Mucinous and non-Mucinous Histologies.

Tsagkalidis V, Choe J, Beninato T, Eskander M, Grandhi M, In H Ann Surg Oncol. 2024; 31(7):4203-4212.

PMID: 38594579 PMC: 11164803. DOI: 10.1245/s10434-024-15233-9.

Insulin and glycolysis dependency of cardioprotection by nicotinamide riboside.

Xiao Y, Wang Q, Zhang H, Nederlof R, Bakker D, Siadari B Basic Res Cardiol. 2024; 119(3):403-418.

PMID: 38528175 PMC: 11142987. DOI: 10.1007/s00395-024-01042-4.

References

Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M . Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics. 2008; 8(16):3329-41. DOI: 10.1002/pmic.200800040. View

Ko Y, Park S, Jung C, Won H, Hong S, Park J . Clinical characteristics and prognostic factors for primary appendiceal carcinoma. Asia Pac J Clin Oncol. 2010; 6(1):19-27. DOI: 10.1111/j.1743-7563.2010.01276.x. View

Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S . Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int. 2011; 61(12):697-716. DOI: 10.1111/j.1440-1827.2011.02734.x. View

OConnell J, Hacker C, Barsky S . MUC2 is a molecular marker for pseudomyxoma peritonei. Mod Pathol. 2002; 15(9):958-72. DOI: 10.1097/01.MP.0000026617.52466.9F. View

Yamada N, Kitamoto S, Yokoyama S, Hamada T, Goto M, Tsutsumida H . Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics. 2012; 2(2):85-96. PMC: 3365379. DOI: 10.1007/s13148-011-0037-3. View

Hirono S, Yamaue H, Hoshikawa Y, Ina S, Tani M, Kawai M . Molecular markers associated with lymph node metastasis in pancreatic ductal adenocarcinoma by genome-wide expression profiling. Cancer Sci. 2009; 101(1):259-66. PMC: 11159850. DOI: 10.1111/j.1349-7006.2009.01359.x. View

Chu P, Chung L, Weiss L, Lau S . Determining the site of origin of mucinous adenocarcinoma: an immunohistochemical study of 175 cases. Am J Surg Pathol. 2011; 35(12):1830-6. DOI: 10.1097/PAS.0b013e3182299c25. View

Hamada T, Wakamatsu T, Miyahara M, Nagata S, Nomura M, Kamikawa Y . MUC4: a novel prognostic factor of oral squamous cell carcinoma. Int J Cancer. 2011; 130(8):1768-76. DOI: 10.1002/ijc.26187. View

McCusker M, Cote T, Clegg L, Sobin L . Primary malignant neoplasms of the appendix: a population-based study from the surveillance, epidemiology and end-results program, 1973-1998. Cancer. 2002; 94(12):3307-12. DOI: 10.1002/cncr.10589. View

10.

Shibahara H, Tamada S, Goto M, Oda K, Nagino M, Nagasaka T . Pathologic features of mucin-producing bile duct tumors: two histopathologic categories as counterparts of pancreatic intraductal papillary-mucinous neoplasms. Am J Surg Pathol. 2004; 28(3):327-38. DOI: 10.1097/00000478-200403000-00005. View

11.

Leroy X, Gouyer V, Ballereau C, Zerimech F, Huet G, Copin M . Quantitative RT-PCR assay for MUC3 and VEGF mRNA in renal clear cell carcinoma: relationship with nuclear grade and prognosis. Urology. 2003; 62(4):771-5. DOI: 10.1016/s0090-4295(03)00560-0. View

12.

Higashi M, Yonezawa S, Ho J, Tanaka S, Irimura T, Kim Y . Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 1999; 30(6):1347-55. DOI: 10.1002/hep.510300609. View

13.

Rakha E, Boyce R, Abd El-Rehim D, Kurien T, Green A, Paish E . Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol. 2005; 18(10):1295-304. DOI: 10.1038/modpathol.3800445. View

14.

Streppel M, Vincent A, Mukherjee R, Campbell N, Chen S, Konstantopoulos K . Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. Hum Pathol. 2012; 43(10):1755-63. PMC: 3547617. DOI: 10.1016/j.humpath.2012.01.005. View

15.

Lee J, Lee J, Kim A, Kim I, Chae Y . Unique expression of MUC3, MUC5AC and cytokeratins in salivary gland carcinomas. Pathol Int. 2005; 55(7):386-90. DOI: 10.1111/j.1440-1827.2005.01842.x. View

16.

Basturk O, Khayyata S, Klimstra D, Hruban R, Zamboni G, Coban I . Preferential expression of MUC6 in oncocytic and pancreatobiliary types of intraductal papillary neoplasms highlights a pyloropancreatic pathway, distinct from the intestinal pathway, in pancreatic carcinogenesis. Am J Surg Pathol. 2010; 34(3):364-70. PMC: 3160822. DOI: 10.1097/PAS.0b013e3181cf8bb6. View

17.

Shibahara H, Higashi M, Koriyama C, Yokoyama S, Kitazono I, Kurumiya Y . Pathobiological implications of mucin (MUC) expression in the outcome of small bowel cancer. PLoS One. 2014; 9(4):e86111. PMC: 3982950. DOI: 10.1371/journal.pone.0086111. View

18.

Saitou M, Goto M, Horinouchi M, Tamada S, Nagata K, Hamada T . MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol. 2005; 58(8):845-52. PMC: 1770880. DOI: 10.1136/jcp.2004.023572. View

19.

Yoon S, Kim B, Lee H, Kang G, Kim W, Kim Y . Differential protein immunoexpression profiles in appendiceal mucinous neoplasms: a special reference to classification and predictive factors. Mod Pathol. 2009; 22(8):1102-12. DOI: 10.1038/modpathol.2009.74. View

20.

Benedix F, Reimer A, Gastinger I, Mroczkowski P, Lippert H, Kube R . Primary appendiceal carcinoma--epidemiology, surgery and survival: results of a German multi-center study. Eur J Surg Oncol. 2010; 36(8):763-71. DOI: 10.1016/j.ejso.2010.05.025. View